MATA NATHAN L. 4
4 · BELITE BIO, INC · Filed May 8, 2026
Research Summary
AI-generated summary of this filing
Belite Bio (BLTE) CSO Nathan L. Mata Sells Shares
What Happened
Nathan L. Mata, Chief Scientific Officer of Belite Bio, sold a total of 666 American depositary shares (ADS) in four open‑market transactions on May 7, 2026, generating total proceeds of approximately $102,039. The individual trades reported were: 226 shares at $152.45 ($34,453); 428 shares at $153.56 ($65,725); 3 shares at $154.61 ($464); and 9 shares at $155.25 ($1,397). These were sales (routine disposition), not purchases.
Key Details
- Transaction date: May 7, 2026; Form 4 filed May 8, 2026 (timely).
- Total sold: 666 ADS for total proceeds ≈ $102,039.
- Reported prices: $152.35–$155.29 (individual trade prices listed above).
- Footnotes: Trades were executed under a Rule 10b5‑1 trading plan adopted 12/10/2025 (F2). Weighted‑average price ranges and willingness to provide per‑price breakdown are noted in footnotes F3–F5. F1 notes each ADS represents one ordinary share.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Transaction code: S = Sale.
Context
Sales executed under a pre‑arranged 10b5‑1 plan are scheduled dispositions and are common for insiders managing personal tax or diversification needs; they do not, by themselves, indicate a change in insider sentiment. No other derivative exercises, gifts, or tax‑withholdings were reported in the provided transaction lines.
Insider Transaction Report
- Sale
American depositary share
[F1][F2][F3]2026-05-07$152.45/sh−226$34,453→ 440 total - Sale
American depositary share
[F1][F2][F4]2026-05-07$153.56/sh−428$65,725→ 12 total - Sale
American depositary share
[F1][F2]2026-05-07$154.61/sh−3$464→ 9 total - Sale
American depositary share
[F1][F2][F5]2026-05-07$155.25/sh−9$1,397→ 0 total
Footnotes (5)
- [F1]Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
- [F3]Represents the weighted average price of shares sold at prices that ranged from $152.35 to $152.68. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F4]Represents the weighted average price of shares sold at prices that ranged from $153.1 to $153.92. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F5]Represents the weighted average price of shares sold at prices that ranged from $155.18 to $155.29. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.